Financial giants have made a conspicuous bullish move on Viking Therapeutics. Our analysis of options history for Viking Therapeutics (NASDAQ:VKTX) revealed 11 unusual trades.
Delving into the details, we found 45% of traders were bullish, while 36% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $78,002, and 9 were calls, valued at $1,174,199.
Expected Price Movements
After evaluating the trading volumes and Open Interest, it’s evident that the major market movers are focusing on a price band between $68.0 and $130.0 for Viking Therapeutics, spanning the last three months.
Insights into Volume & Open Interest
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Viking Therapeutics’s options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Viking Therapeutics’s significant trades, within a strike price range of $68.0 to $130.0, over the past month.
Viking Therapeutics Option Volume And Open Interest Over Last 30 Days
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VKTX | CALL | TRADE | BEARISH | 08/16/24 | $10.4 | $9.6 | $9.7 | $80.00 | $582.0K | 419 | 7 |
| VKTX | CALL | TRADE | BULLISH | 06/21/24 | $6.5 | $4.5 | $6.5 | $75.00 | $110.5K | 2.6K | 184 |
| VKTX | CALL | SWEEP | NEUTRAL | 06/21/24 | $6.3 | $6.0 | $6.3 | $75.00 | $107.1K | 2.6K | 355 |
| VKTX | CALL | TRADE | BEARISH | 06/21/24 | $5.2 | $4.9 | $4.9 | $80.00 | $83.3K | 2.2K | 214 |
| VKTX | CALL | TRADE | BULLISH | 06/21/24 | $6.5 | $6.0 | $6.4 | $75.00 | $81.2K | 2.6K | 483 |
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company’s clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Following our analysis of the options activities associated with Viking Therapeutics, we pivot to a closer look at the company’s own performance.
Viking Therapeutics’s Current…
Click Here to Read the Full Original Article at Cryptocurrencies Feed…
